Clinical trial for NHL
Official title IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
ClinicalTrials.gov ID: NCT06119685
What this study is testing
What is IDP-023?
IDP-023 is an investigational medicine, being studied as a potential treatment for nhl.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to see if IDP-023 is safe and tolerable and to get early clues about its effect on tumors.
- Who it's for
- Adults who have relapsed or refractory non‑Hodgkin lymphoma or multiple myeloma.
- What's involved
- Participants receive IDP-023 by itself or together with interleukin‑2 and/or antibodies such as isatuximab, daratumumab or rituximab, with dose levels increased over time, plus regular check‑ups and lab tests.
- Time commitment
- The trial runs for several months, requiring multiple clinic visits for dosing and safety monitoring.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- For MM patients: Documented diagnosis of MM requiring systemic therapy and relapsed and/or refractory (R/R) disease after ≥ 3 prior lines of therapy.
- For NHL patients: R/R disease and failed ≥ 2 lines of systemic chemotherapy.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Life expectancy of greater than 12 weeks per the Investigator. Key
You likely can't join if
- Impaired cardiac function or history of clinical significant cardiac disease.
- Human immunodeficiency virus (HIV) infection, active hepatitis B infection, or hepatitis C infection.
- Active SARS-CoV-2 infection.
- Has untreated central nervous system, epidural tumor metastasis, or brain metastasis.
The study team makes the final eligibility decision.
Where it is enrolling
- Los Angeles, California, United States
- Atlanta, Georgia, United States
- Minneapolis, Minnesota, United States
- Winston-Salem, North Carolina, United States
- Cleveland, Ohio, United States
- Providence, Rhode Island, United States
- Nashville, Tennessee, United States
- Houston, Texas, United States
- Fairfax, Virginia, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Los Angeles, California, United States; Atlanta, Georgia, United States; Minneapolis, Minnesota, United States; Winston-Salem, North Carolina, United States; Cleveland, Ohio, United States; Providence, Rhode Island, United States and 3 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.